Complete Filing Data
Medicus Pharma Ltd. reported Stockholders Equity Including Portion Attributable To Noncontrolling Interest of $37.3 thousand for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Medicus Pharma Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income * | -$47.3M | -$11.2M | -$5.3M |
| Research And Development Expense | $7.7M | $3.5M | $193.6K |
| Other Nonoperating Income Expense | -$1.1M | $25.4K | -$584.8K |
| Operating Income Loss | -$34.4M | -$11.2M | -$4.7M |
| Operating Expenses | $34.4M | $11.2M | $4.7M |
| General And Administrative Expense | $17.9M | $7.7M | $4.5M |
| Interest Income Expense Net | -$197.4K | $25.4K | |
| Research And Development Expense Excluding Acquired In Process Cost | $8.7M | $0.00 | |
| Net Income Loss Attributable To Noncontrolling Interest | -$146.00 | $0.00 | |
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | -$150.00 | $0.00 | |
| Comprehensive Income Net Of Tax | -$47.3M | -$11.2M | |
| Net Income Loss Available To Common Stockholders Basic | -$47.3M | -$11.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income * | -$20.9M | -$6.2M | -$5.1M | -$2.3M | -$3.6M | -$1.7M |
| Research And Development Expense | $1.7M | $1.4M | $2.0M | $564.1K | $1.3M | $321.4K |
| Other Nonoperating Income Expense | -$555.0K | -$160.0K | $23.9K | $55.5K | -$79.0K | $0.00 |
| Operating Income Loss | -$15.00 | -$6.0M | -$5.1M | -$2.3M | -$3.6M | -$1.7M |
| Operating Expenses | $15.00 | $6.0M | $5.1M | $2.3M | $3.6M | $1.7M |
| General And Administrative Expense | $5.00 | $4.6M | $3.1M | $1.8M | $2.3M | $1.4M |
| Interest Income Expense Net | $11.6K | $40.0K | $55.5K | -$79.0K | ||
| Research And Development Expense Excluding Acquired In Process Cost | $8.7M | $0.00 | ||||
| Net Income Loss Attributable To Noncontrolling Interest | -$77.00 | $0.00 | ||||
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | $75.00 | $0.00 | ||||
| Comprehensive Income Net Of Tax | -$2.00 | -$2.3M | ||||
| Net Income Loss Available To Common Stockholders Basic | -$2.3M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity * | -$67.6K | $3.1M | $1.1M | -$12.2M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $8.7M | $4.2M | $1.7M | $267.7K |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $0.00 | $356.8K | $0.00 | |
| Retained Earnings Accumulated Deficit | -$64.3M | -$28.9M | -$17.7M | |
| Related Party Payable Current | $116.5K | $142.5K | $166.0K | |
| Operating Lease Right Of Use Asset | $170.7K | $268.6K | $0.00 | |
| Operating Lease Liability Noncurrent | $60.1K | $205.9K | $0.00 | |
| Operating Lease Liability Current | $145.5K | $116.3K | $0.00 | |
| Liabilities Current | $9.9M | $2.3M | $781.6K | |
| Liabilities And Stockholders Equity | $10.1M | $5.6M | $1.9M | |
| Liabilities | $10.0M | $2.5M | $781.6K | |
| Issuance Costs Included In Accounts Payable | $95.4K | $265.0K | $0.00 | |
| Common Stock Value | $57.1M | $30.5M | $18.8M | |
| Common Stock No Par Value | $0.00 | $0.00 | $0.00 | |
| Cash And Cash Equivalents At Carrying Value | $8.7M | $4.2M | $1.7M | |
| Assets Current | $9.9M | $5.4M | $1.9M | |
| Assets | $10.1M | $5.6M | $1.9M | |
| Accrued Liabilities And Other Liabilities | $995.3K | $762.8K | $404.8K | |
| Accounts Payable Current | $3.4M | $1.3M | $210.8K | |
| Gains Losses On Extinguishment Of Debt | -$25.0K | $0.00 | ||
| Debt Current | $5.2M | $0.00 | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $2.4M | $1.5M | ||
| Stock Issued During Period Value Conversion Of Debt | $5.2M | |||
| Repayments Of Debt | $7.4M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Stockholders Equity * | -$910.1K | $3.2M | $2.1M | $4.8M | $7.1M | -$560.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $8.7M | $9.7M | $4.0M | $5.3M | $8.4M | $542.4K |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $0.00 | $356.8K | ||||
| Retained Earnings Accumulated Deficit | -$5.00 | -$40.2M | -$34.0M | |||
| Related Party Payable Current | $143.1K | $121.3K | $118.2K | |||
| Operating Lease Right Of Use Asset | $196.2K | $221.0K | $245.1K | |||
| Operating Lease Liability Noncurrent | $95.2K | $141.8K | $174.4K | |||
| Operating Lease Liability Current | $141.1K | $124.4K | $120.3K | |||
| Liabilities Current | $10.7M | $8.5M | $3.3M | |||
| Liabilities And Stockholders Equity | $10.0M | $11.9M | $5.7M | |||
| Liabilities | $10.8M | $8.7M | $3.5M | |||
| Issuance Costs Included In Accounts Payable | $95.1K | $0.00 | ||||
| Common Stock Value | $4.00 | $37.8M | $32.9M | |||
| Common Stock No Par Value | $0.00 | $0.00 | $0.00 | |||
| Cash And Cash Equivalents At Carrying Value | $8.7M | $9.7M | $4.0M | |||
| Assets Current | $9.8M | $11.0M | $5.1M | |||
| Assets | $10.0M | $11.9M | $5.7M | |||
| Accrued Liabilities And Other Liabilities | $1.6M | $1.8M | $1.1M | |||
| Accounts Payable Current | $2.0M | $1.8M | $2.0M | |||
| Gains Losses On Extinguishment Of Debt | -$25.0K | $0.00 | ||||
| Debt Current | $6.8M | $4.7M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$181.9K | -$1.2M | ||||
| Stock Issued During Period Value Conversion Of Debt | $5.2M | |||||
| Repayments Of Debt |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $1.5M | $713.1K | $98.6K |
| Net Cash Provided By Used In Operating Activities | -$22.8M | -$10.2M | -$4.2M |
| Net Cash Provided By Used In Financing Activities | $31.9M | $12.7M | $5.6M |
| Increase Decrease In Prepaid Expense | -$352.8K | $1.0M | $158.7K |
| Increase Decrease In Operating Lease Rightofuse Assets | $97.8K | $88.2K | $0.00 |
| Increase Decrease In Operating Lease Liability | -$142.6K | -$70.1K | $0.00 |
| Increase Decrease In Accounts Payable Related Parties | -$26.0K | -$23.5K | $166.0K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$438.8K | $358.0K | $386.8K |
| Proceeds From Convertible Debt | $0.00 | $5.2M | $500.0K |
| Proceeds From Issuance Of Common Stock | $9.8M | $5.5M | $0.00 |
| Proceeds From Warrant Exercises | $9.9M | $0.00 | |
| Proceeds From Issuance Of Debt | $11.9M | $0.00 | |
| Increase Decrease In Deferred Charges | $99.3K | $0.00 | |
| Increase Decrease In Costs To Issue Debentures | $111.7K | $0.00 | |
| Increase Decrease In Change In Fair Value Of Debentures | $583.8K | $0.00 | |
| Increase Decrease In Accounts Payable | $808.7K | $79.1K | |
| Proceeds From Stock Options Exercised | $162.4K | $0.00 | |
| Proceeds From Issuance Of Shares Under Settlements | 8.4M | 0.00 | |
| Proceeds From Issuance Of Common Shares And Warrants | |||
| Proceeds From Issuance Initial Public Offering | $0.00 | $2.0M | $0.00 |
| Payments Of Stock Issuance Costs | $653.5K | $0.00 | |
| Payments Of Financing Costs | |||
| Net Cash Provided By Used In Investing Activities | -$4.6M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 |
|---|---|---|
| Share Based Compensation | $112.3K | $36.0K |
| Net Cash Provided By Used In Operating Activities | -$3.9M | -$1.2M |
| Net Cash Provided By Used In Financing Activities | $3.8M | $0.00 |
| Increase Decrease In Prepaid Expense | -$122.6K | -$61.6K |
| Increase Decrease In Operating Lease Rightofuse Assets | $23.5K | $30.9K |
| Increase Decrease In Operating Lease Liability | -$27.6K | $0.00 |
| Increase Decrease In Accounts Payable Related Parties | -$24.2K | $47.3K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $299.2K | -$9.7K |
| Proceeds From Convertible Debt | ||
| Proceeds From Issuance Of Common Stock | ||
| Proceeds From Warrant Exercises | ||
| Proceeds From Issuance Of Debt | ||
| Increase Decrease In Deferred Charges | ||
| Increase Decrease In Costs To Issue Debentures | ||
| Increase Decrease In Change In Fair Value Of Debentures | ||
| Increase Decrease In Accounts Payable | $655.6K | $364.3K |
| Proceeds From Stock Options Exercised | ||
| Proceeds From Issuance Of Shares Under Settlements | ||
| Proceeds From Issuance Of Common Shares And Warrants | 3.8M | 0.00 |
| Proceeds From Issuance Initial Public Offering | ||
| Payments Of Stock Issuance Costs | ||
| Payments Of Financing Costs | $25.0K | $0.00 |
| Net Cash Provided By Used In Investing Activities |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 17.3M | 9.6M | 3.5M |
| Weighted Average Number Of Diluted Shares Outstanding | 17.3M | 9.6M | 3.5M |
| Earnings Per Share Diluted | $-2.74 | $-1.16 | $-1.53 |
| Earnings Per Share Basic | $-2.74 | $-1.16 | $-1.53 |
| Common Stock Shares Outstanding | 25.2M | 11.8M | 8.1M |
| Common Stock Shares Issued | 25.2M | 11.8M | 8.1M |
| Shares Issued For Acquisition Of Antev | 2.1M | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 18.6M | 14.3M | 12.2M | 9.5M | 8.2M | 8.1M |
| Weighted Average Number Of Diluted Shares Outstanding | 18.6M | 14.3M | 12.2M | 9.5M | 8.2M | 8.1M |
| Earnings Per Share Diluted | $-1.12 | $-0.43 | $-0.42 | $-0.24 | $-0.44 | $-0.21 |
| Earnings Per Share Basic | $-1.12 | $-0.43 | $-0.42 | $-0.24 | $-0.44 | $-0.21 |
| Common Stock Shares Outstanding | 21.0M | 15.9M | 13.4M | |||
| Common Stock Shares Issued | 21.0M | 15.9M | 13.4M | |||
| Shares Issued For Acquisition Of Antev |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.5M | $713.1K | $98.6K |
| Prepaid Expense Current | $1.1M | $1.2M | $173.7K |
| Change In Fair Value Of Debentures | -$583.8K | $0.00 | |
| Additional Paid In Capital | $6.9M | $1.5M | $98.6K |
| Paid In Kind Interest | $429.1K | $74.0K | $584.8K |
| Stock Issued During Period Value Upon Exercise Of Stock Warrants | $9.9M | ||
| Gain Loss On Settlements | -$278.9K | $0.00 | |
| Foreign Currency Transaction Gain Loss Before Tax | -$10.7K | $0.00 | |
| Deemed Dividend On Warrant Inducement | $11.8M | $0.00 | |
| Comprehensive Loss Attributable To Parent | -$47.3M | -$11.2M | |
| Stock Issued During Period Value Connection With Sepa Offering Costs | $9.0M | ||
| Stock Issued During Period Value New Issues | $3.7M | ||
| Shares To Be Issued For Acquisition Of Antev | 313.9K | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $852.8K | $117.4K | $112.3K | $585.4K | $36.0K | |
| Prepaid Expense Current | $1.1M | $1.3M | $1.1M | |||
| Change In Fair Value Of Debentures | -$383.8K | -$200.0K | $0.00 | $0.00 | ||
| Additional Paid In Capital | $6.4M | $5.6M | $3.2M | |||
| Paid In Kind Interest | ||||||
| Stock Issued During Period Value Upon Exercise Of Stock Warrants | $3.8M | $963.4K | $14.0K | |||
| Gain Loss On Settlements | -$157.7K | $0.00 | ||||
| Foreign Currency Transaction Gain Loss Before Tax | $10.8K | $0.00 | ||||
| Deemed Dividend On Warrant Inducement | $5.0M | $0.00 | ||||
| Comprehensive Loss Attributable To Parent | -$20.9M | -$2.3M | ||||
| Stock Issued During Period Value Connection With Sepa Offering Costs | $5.3M | $300.0K | ||||
| Stock Issued During Period Value New Issues | $3.7M | |||||
| Shares To Be Issued For Acquisition Of Antev |
Most recent annual filing with the SEC: March 25, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.